Cargando…

Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin

Clinical trials of biologic agents for chronic active antibody-mediated rejection (CAMR) in kidney transplant recipients (KTRs) have been disappointing. We performed a clinical trial of mesenchymal stem cell (MSC) treatment in KTRs with CAMR unresponsive to rituximab and intravenous immunoglobulin....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ban, Tae Hyun, Lee, Sua, Kim, Hyung Duk, Ko, Eun Jeong, Kim, Bo-Mi, Kim, Kyoung-Woon, Chung, Byung Ha, Yang, Chul Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892211/ https://www.ncbi.nlm.nih.gov/pubmed/33628269 http://dx.doi.org/10.1155/2021/6672644

Ejemplares similares

The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
por: An, Gun Hee, et al.
Publicado: (2014)

Clinical significance of CCR7(+)CD8(+) T cells in kidney transplant recipients with allograft rejection
por: Kim, Kyoung Woon, et al.
Publicado: (2018)

Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment
por: Seo, Euri, et al.
Publicado: (2016)

Clinical significance of CD161(+)CD4(+) T cells in the development of chronic antibody-mediated rejection in kidney transplant recipients
por: Kim, Kyoung Woon, et al.
Publicado: (2018)

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
por: Ahmed, A. Razzaque, et al.
Publicado: (2018)

Impact of ABO Incompatibility on the Development of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients Presensitized to HLA
por: Chung, Byung Ha, et al.
Publicado: (2015)

Profound hyperacute cardiac allograft rejection rescue with biventricular mechanical circulatory support and plasmapheresis, intravenous immunoglobulin, and rituximab therapy
por: Kaczorowski, David J, et al.
Publicado: (2013)

Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease
por: Piram, Maryam, et al.
Publicado: (2020)

Two PerPLEXing Cases of Hashimoto’s Encephalopathy Unresponsive to Steroid and Intravenous Immunoglobulin Therapy
por: Karan, Abhinav, et al.
Publicado: (2022)

Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient
por: Dashti-Khavidaki, Simin, et al.
Publicado: (2015)

Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group
por: Song, Young Hae, et al.
Publicado: (2012)

Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients
por: Park, Hoon Suk, et al.
Publicado: (2014)

Intravenous Immunoglobulin Controls Th17 Cell-Mediated Osteoclastogenesis
por: Kim, Kyoung-Woon, et al.
Publicado: (2019)

Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection
por: Piñeiro, Gastón J, et al.
Publicado: (2018)

Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding
por: Cugno, Massimo, et al.
Publicado: (2014)

Increase of Th17 Cell Phenotype in Kidney Transplant Recipients with Chronic Allograft Dysfunction
por: Chung, Byung Ha, et al.
Publicado: (2015)

Phenotype and molecular signature of CD8(+) T cell subsets in T cell- mediated rejections after kidney transplantation
por: Ko, Eun Jeong, et al.
Publicado: (2020)

Rejection-triggered haemophagocytic syndrome in renal transplantation successfully treated with intravenous immunoglobulin
por: Marques, Igor Denizarde Bacelar, et al.
Publicado: (2013)

Recipient natural killer cells alter the course of rejection of allogeneic heart grafts in rats
por: Beetz, Oliver, et al.
Publicado: (2019)

Allogeneic tumor rejection induced by the intravenous injection of Lyt- 2+ cytolytic T lymphocyte clones
Publicado: (1982)

Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: A case report
por: Zhang, Weihe, et al.
Publicado: (2022)

Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab
por: Vasconcelos, Joana, et al.
Publicado: (2021)

A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease
por: Amano, Yuji, et al.
Publicado: (2019)

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016)

Amyloid light-chain amyloidosis presented as focal segmental glomerulosclerosis in a kidney transplant recipient
por: Park, Sung Hyun, et al.
Publicado: (2020)

Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients
por: Lee, Hyeyoung, et al.
Publicado: (2016)

Long-Term Follow-Up after Intravenous Immunoglobulin Therapy in Patients with Severe Ocular Mucous Membrane Pemphigoid Unresponsive to Conventional Therapy
por: Leuci, Stefania, et al.
Publicado: (2018)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Angiotensin II Type 1 Receptor Antibody-Mediated Kidney Rejection Unresponsive to Treatment
por: Allison, David, et al.
Publicado: (2023)

Rituximab and intravenous immunoglobulin treatment in PM/Scl antibody-associated disease: case-based review
por: Srikantharajah, Denesh, et al.
Publicado: (2022)

Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments
por: Massa, Federico, et al.
Publicado: (2022)

Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results
por: Mella, Alberto, et al.
Publicado: (2018)

BK virus encephalitis without concurrent hemorrhagic cystitis in an allogeneic hematopoietic stem cell transplant recipient
por: Lee, Suk-young, et al.
Publicado: (2013)

Rituximab use in late antibody-mediated rejection
por: Bansal, S. B.
Publicado: (2016)

Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients
por: Pilon, Caroline, et al.
Publicado: (2020)

Impact of high body mass index on allograft outcomes in kidney transplant recipients with presensitization to human leukocyte antigen
por: Park, Yohan, et al.
Publicado: (2021)

Susac Syndrome With Good Response to Intravenous Immunoglobulin: A Case Report
por: Kim, Seokhyun, et al.
Publicado: (2023)

Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
por: Jung, Sung-Hoon, et al.
Publicado: (2012)

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017)

Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
por: Kim, Young Hoon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2ges0prbben7arfa9h54bgpb76